Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05216432
Title First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Relay Therapeutics, Inc.
Indications

head and neck squamous cell carcinoma

Her2-receptor negative breast cancer

ovarian clear cell carcinoma

cervical cancer

Advanced Solid Tumor

Therapies

RLY-2608

Fulvestrant + RLY-2608

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST